CHRS
Coherus Biosciences
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 2
consensus rating "Strong Buy"
EPS Below Expectations
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CHRS
Coherus Biosciences, Inc.
A commercial stage biopharmaceutical company that builds a leading immuno-oncology franchise
333 Twin Dolphin Drive, Suite 600, Redwood City, California 94065
--
Coherus Biosciences, Inc., was incorporated in Delaware in September 2010. The Company is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and the commercialization of approved biosimilar combinations. The company's strategy is to build a leading immuno-oncology franchise, funded by cash generated through net sales of a diverse portfolio of U.S. Food and Drug Administration-approved therapies.
Company Financials
EPS
CHRS has released its 2024 Q4 earnings. EPS was reported at -0.28, versus the expected -0.13, missing expectations. The chart below visualizes how CHRS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CHRS has released its 2024 Q4 earnings report, with revenue of 54.14M, reflecting a YoY change of -40.84%, and net profit of -50.70M, showing a YoY change of 36.35%. The Sankey diagram below clearly presents CHRS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
